Posts Tagged: partnerships with industry

Ontario Government Invests $1 Million in Toronto’s Neuroscience Catalyst Consortium

Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer's disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million ... Read more

Sunnybrook forms new industry partnership to advance WaveCheck technology

Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy. This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views. The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck ... Read more

Triphase Accelerator announces new cancer collaboration with Sunnybrook Research Institute

TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor. Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR ... Read more

CoursePeer and National Franchise Group partner to launch Franchise University

Signarama Canada first global franchise group to rollout solution TORONTO, January 29, 2015  — CoursePeer Inc. and National Franchise Group have partnered to launch Franchise University, a service offering global franchise groups a powerful cloud-based training and collaboration solution for their franchisees. Signarma Canada, the global sign industry leader ranked 28th on Franchise Direct's Top 100 Global Franchises list, is among the first brands to join. CoursePeer, a University of Toronto and MaRS Innovation company that provides learning and collaboration solutions for enterprise ... Read more

Funding call: MaRS Innovation Industry Access Program (MI-IAP) accepting applications to February 6

Researchers working in orphan indications, immuno-oncology, respiratory diseases, diabetes, and other key areas invited to submit a brief Statement of Interest The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and IRICoR/Merck. The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs. The program is open to any researcher affiliated with MI's 16 member ... Read more

MaRS Innovation collaborating with Johnson & Johnson Innovation and Janssen to advance Cardiac, Diabetes and Depression technologies

TORONTO, Jan. 12, 2015  — MaRS Innovation, the commercialization agent for Ontario's 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation, LLC and its Canadian affiliate, Janssen Inc., to advance three technologies focused on cardiac, diabetes and depression, respectively. This announcement was covered in Lab Product News. "These three projects reflect the quality of innovation present in Toronto's research community for our industry partners, and Toronto's progress in addressing healthcare issues of international concern," ... Read more

SciBX covers Encycle’s partnership with IRICoR, MaRS Innovation and Merck

"The first disclosed grant under Merck & Co. Inc.'s Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin [a4b7,] inhibitors for inflammatory bowel disease," writes Michael J. Haas in SciBX's feature on the partnership, "Merck Encycles through Canada." The article appears in the publication's December 4, 2014 issue. Read the Encycle press release that prompted this article. The article explores the current grant partnership between Merck, Encycle Therapeutics, MaRS Innovation, the Institute for ... Read more

Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease

Company's collaborative partnership with IRICoR, Université de Montréal and MaRS Innovation, funded by Merck Canada, to advance macrocycle drug TORONTO and MONTREAL, Nov. 10, 2014 — Encycle Therapeutics Inc., a biotechnology start-up founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease. This announcement was covered in SciBX, Drug Discovery ... Read more

Triphase announces Celgene collaborations and license deal with PharmAbcine

Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, announced October 27, 2014 new and expanded strategic collaborations with Celgene Corporation. This announcement was covered in Genetic Engineering and Biotechnology News (GEN), BioCentury Extra (no link available), Pharmaceutical Business Review (no link available), Scrip and BioWorld Today (no link available). It builds on Triphase's original collaborative agreement with Celgene in January 2014. The company has also announced a new global license for a fully human, bi-specific ... Read more

Vasomune Therapeutics awarded $1.5 million to advance lead asset for renal disease

TORONTO (October 20, 2014) — Vasomune Therapeutics, a biotechnology start-up founded by Drs. Dan Dumont and Paul Van Slyke of Sunnybrook Research Institute (SRI) in partnership with MaRS Innovation, has received $1.5 million, in part through Genome Canada’s Genomic Applications Partnership Program (GAPP), to advance Vasculotide, the company’s lead Tie-2 activating agent, towards clinical development. This announcement was covered in Biotechnology Focus. The Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, announced ... Read more
Page 2 of 512345